Key result
Engineered 5A-APC mutant retains full cytoprotective function with minimal anticoagulant activity vs wild-type APC.
Answers are grounded in this paper and cite their sources.
Activated protein C (APC) reduces mortality in severe sepsis patients and exhibits beneficial effects in multiple animal injury models. APC anticoagulant activity involves inactivation of factors Va and VIIIa, whereas APC cytoprotective activities involve the endothelial protein C receptor and protease-activated receptor-1 (PAR-1). The relative importance of the anticoagulant activity of APC versus the direct cytoprotective effects of APC on cells for the in vivo benefits is unclear. To distinguish cytoprotective from the anticoagulant activities of APC, a protease domain mutant, 5A-APC (RR229/230AA and KKK191-193AAA), was made and compared with recombinant wild-type (rwt)-APC. This mutant had minimal anticoagulant activity but normal cytoprotective activities that were dependent on endothelial protein C receptor and protease-activated receptor-1. Whereas anticoagulantly active rwt-APC inhibited secondary-extended thrombin generation and concomitant thrombin-dependent activation of thrombin activable fibrinolysis inhibitor (TAFI) in plasma, secondary-extended thrombin generation and the activation of TAFI were essentially unopposed by 5A-APC due to its low anticoagulant activity. Compared with rwt-APC, 5A-APC had minimal profibrinolytic activity and preserved TAFI-mediated anti-inflammatory carboxypeptidase activities toward bradykinin and presumably toward the anaphlatoxins, C3a and C5a, which are well known pathological mediators in sepsis. Thus, genetic engineering can selectively alter the multiple activities of APC and provide APC mutants that retain the beneficial cytoprotective effects of APC while diminishing bleeding risk due to reduction in APC's anticoagulant and APC-dependent profibrinolytic activities.
No takes yet. Share an insight, caveat, or question.
Mosnier et al. (2007) studied Sepsis. 5A-APC (activated protein C protease domain mutant RR229/230AA and KKK191-193AAA) vs. Recombinant wild-type activated protein C (rwt-APC) was evaluated on Anticoagulant, profibrinolytic, and EPCR/PAR-1- and TAFI-dependent cytoprotective activities in vitro/plasma. The engineered 5A-APC mutant exhibited minimal anticoagulant and profibrinolytic activity compared with wild-type APC while preserving normal EPCR/PAR-1 and TAFI-dependent cytoprotective functions.
Synapse has enriched 10 related papers. Consider them for comparative context: